Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anakinra Clear all
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade in HF With Preserved EF

NCT02173548
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 8, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

NCT00069329
View directory record Official record
Conditions
Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions
anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

NCT03797001
View directory record Official record
Conditions
Heart Failure, Systolic, Inflammation
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Early Treatment of Cytokine Storm Syndrome in Covid-19

NCT04362111
View directory record Official record
Conditions
Cytokine Storm, COVID-19
Interventions
Anakinra, Normal saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

MIS-C Comparative Effectiveness Study

NCT04898231
View directory record Official record
Conditions
Multisystem Inflammatory Syndrome-Children
Interventions
Infliximab, Anakinra, Methylprednisolone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 20 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Diego, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 8, 2026, 2:24 PM EDT
Recruiting Phase 2Phase 3 Interventional

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

NCT05267821
View directory record Official record
Conditions
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Day to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 8, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension

NCT01479010
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Anakinra 100 mg subcutaneously daily
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 8, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT02930122
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
anakinra (150mg), Saline intraarticularly
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT04150913
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
Interventions
Anakinra, Axicabtagene Ciloleucel
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 8, 2026, 2:24 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 8, 2026, 2:24 PM EDT
Not listed Early Phase 1 Interventional

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms

NCT03991520
View directory record Official record
Conditions
Endometriosis, Anakinra, Markers of Inflammation
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

NCT01624766
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Anakinra, Denosumab, Everolimus
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra for Behcet s Disease

NCT01441076
View directory record Official record
Conditions
Autoimmune Connective Tissue Disorder, Immune System Diseases
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 8, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Acute Pericarditis With Anakinra

NCT03224585
View directory record Official record
Conditions
Acute Pericarditis
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

NCT04747847
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Atorvastatin and anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Year to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 8, 2026, 2:24 PM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure

NCT01300650
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04025554
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 8, 2026, 2:24 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience

NCT05074485
View directory record Official record
Conditions
Pain
Interventions
anakinra, Placebo, Nociceptive pain challenge
Drug · Other
Lead sponsor
Alan Prossin
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 8, 2026, 2:24 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

NCT00897715
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 8, 2026, 2:24 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

NCT04119687
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
FX201
Biological
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Sarasota, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 8, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

NCT02179853
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Month to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 8, 2026, 2:24 PM EDT